AstraZeneca’s EvuSheld Receives Market Authorization Recommendation by CHMP

March 25, 2022

The EU’s Committee for Medicinal Products for Human Use (CHMP) has released their recommendation that the COVID-19 preventative treatment Evusheld receive marketing authorization. The drug, a long-acting antibody, offers a 77% reduction in rates of symptomatic COVID-19 for the three million people for whom COVID-19 vaccines are ineffective, primarily immunocompromised people. As demonstrated in the PROVENT phase three trial, protection was durable, with an 83% reduction in infectionsat 6 months.

Accodring to PM Live, Mene Pangalos, executive VP of BioPharmaceuticals R&D at Astrazeca, “Evusheld has the potential to provide long-lasting protection to vulnerable populations such as the immunocompromised who can’t mount an adequate response to a COVID-19 vaccine, and we’ll continue to work with governments in Europe to make Evusheld available as quickly as possible.”